Advances in bioavailability. Innovations in delivery technologies and dose forms. Proven results from our team of scientists, researchers, and regulatory experts.
Whatever your challenge, we have an expert who can solve it.
Transition from preliminary formulation to commercial drug launch, quickly & cost-effectively.
Unique Consumer Health solutions for OTC, Supplements & Beauty.
Deliver more differentiated dietary supplement products, faster to market.
Strategies and tactics to develop new antibody biosmilar products.
Oral dose development with optimal therapeutic performance.
Ideal solution for consumers seeking an animalfree alternative to gelatin capsules.
Develop liquid capsule fill formulations that are mitigated to prevent abuse.
Limit individual variability of type I & II systems with adequate choice of composition.
Handle small amounts of API or formulation at the early stages of development.
Reduce the potential for iatrogenic transmission of pathogenic viruses.
Design a safe, effective & stable dosage form, and ensure patient compliance.
Successfully achieve taste-masking while maintaining release characteristics.
Develop oral dosage forms of water-insoluble compounds with amorphous solid dispersions.
Monitor crystalline state of a compound during stability studies.
Incorporate high concentrations of various oils in an ODT.
Integrated, tailored solutions to accelerate your path to market.
Enable expanded biotechnology applications of the aldehyde tag.
Reduce the risks associated with traditional aseptic manufacturing.
Deliver compliance and flexibility with a convenient, enjoyable dose form.
Improve compatibility with wider range of excipients to enhance bioavailability & stability.
Risk management to reduce the potential for iatrogenic transmission of pathogenic viruses.
Ease of administration to achieve long-term patient compliance & optimal therapeutic outcomes.
Lipid-based drug-delivery systems to assist in the delivery of poorly soluble drugs.
Reduce supply-related risks related to biosimilar product availability, cost & quality.
Perform dosage form selection in the early phases of drug development.
Chewable technology that is ideal to deliver active ingredients, without the need for water.
Potent compound handling to ensure success for complex & possibly dangerous HPAPIs.
Advanced technology platforms to enhance many biotherapeutics including ADCs.
Generating uniform site-specific ADCs utilizing a chemoenzymatic approach.
Offer new preferred benefits and improved efficacy to achieve differentiation.
Ways of increasing ADC stability and efficacy are still required for these therapies.
Optimize manufacturing parameters like lower processing temperature & thinner softgel shell.
Complex, specialized requirements in micronization, to handle the toughest specifications.
Advanced aseptic glass-free delivery solution for injectable treatments.
The toolkit of technologies based upon lipid-based drug delivery systems.
Achieving a 40-fold increase in production of the antibody.
The cytotoxicity of HPAPIs presents handling challenges.
Choose the right technology to develop an efficient Phase I enabling drug product
Drug delivery solutions need to become more sophisticated and more effective.
in OptiMelt™ Hot Melt Extrudates for Development of Stable Final Dosage Forms
Prepared by OptiMelt™ Hot Melt Extrusion for Optimized Oral Solid Dosage Forms
One such technology that minimizes the risk in biologics processing is ADVASEPT® technology.
An appropriate formulation often requires significant API material.
Solubility screening approaches that can save both time and money.
Scientists now have an arsenal of drug delivery techniques to choose from.
Proven and versatile particle size reduction, micronization and milling technologies
Deliver higher API concentrations in smaller capsules for patient benefits.
Process, analytical, and manufacturing essential for biosimilar development programs.
OptiPact™ Technology, capabilities for Orphan Drugs & Catalent's factors of differentiation.
Reduce the struggle to administer medication to animal populations.
Overcome dose acceptance and therapeutic compliance hurdles.
Macromolecule delivery by targeted delivery and enteric coating techniques.
BASF & Catalent experts discuss the development of HME oral solid dosage forms.
Macromolecules can potentially be converted from injectable to oral drug delivery.
A proven solution for improving physical stability of many oral formulations.
Discover what constitutes an Advanced Asceptic Process and the numerous advantageous.
The path to successfully marketing a biosimilar product and global regulatory environment.
Switching from small to large molecules in pharma, cell line expression and emerging markets.
The future of site-specific conjugation to improve CMC production and therapeutic index.
Innovative oral softgel platform capable of delivering multiple actives.
Learn the fundamentals of the advanced aseptic process utilizing BFS technology.
Learn about how softgel technologies can address API and processing challenges.
Learn more about integrating formulation technology in drug development.
Learn about two major changes to the USP pertaining to <231> & <661>.
BFS technology has been expanding into injectables and into biologics.
Graduate students in pharmaceutical sciences provide commentary on drug delivery topics.
Catalent continues its legacy of innovation with OptiGel Bio™ technology—expanding the versatility of softgel technology to enable the potential oral delivery of macromolecule therapies.
Bio-Layer Interferometry can be a useful tool for characterizing biosimilars
Developing orphan drugs to treat rare diseases is an industry priority.
How integrated development programs can be used to mitigate risk and reduce timelines.
New technology enables a brand to keep its leading market position.
RP Scherer Technology can improve timelines and commercialization potential.
We can help you bring more products to market faster and support your business objectives of driving brand growth and market share. Get to market faster with our library of non-prescription analgesic and cough, cold & allergy softgel products.
Insights in order to eliminate risk inherent to sterile manufacturing environments.
Catalent is using rational conjugate design with selective drug placement.
Learn about Orphan drug development and other fast track product development pathways.
Compatibility of model mAb formulation in glass and Advasept® Vials.
Development of a single process configuration that reduces cost and decreases time.
This project was aimed to develop and fully validate an UPLC method.
This on-demand webinar will identify ways to determine the ideal formulation for your molecule
Catalent Schordorf has expanded controlled release and hot melt extrusion capabilities
Bioconjugates show great promise to improve existing therapeutics.
Learn more about the challenge of continuous supply available to meet clinical study needs,
Commercial success of a drug can be influenced by patient’s perception of the formulation.
Catalent worked with the client to bring a vastly superior sublingual product to market.
Creation of a custom packaging/distribution concept to meet the client’s needs.
Creation of a custom packaging and distribution solution to meet this client’s unique needs.
Identification of the impurities combined with analytical and sample handling challenges.
Case study describing custom batch manufacture of the product at a reasonable cost.
Catalent's OptiGel™ Bio technology can provide a pathway for an IV to oral delivery conversion.
Patient compliance with medication can be especially challenging for pediatric populations.
Extractable and leachable detection methods and best practices.
OsDrC®OptiDose™ is an innovative flexible core tableting technology that enables the formulation and manufacturing of single or multi-cored tablets with differentiated controlled release functionality.
OptiMelt™ broadly addresses bioavailability enhancement factors at any stage of drug development through commercialization, with integrated teams of scientists and technologies
SMARTag™ ADC technology enables biologic innovators to develop more efficacious antibody drug conjugates faster.
The first-ever survey investigating patient experiences with clinical trial materials
Learn more about our 26 global sites producing approximately 50 billion capsules for more than 5,000 consumer health products marketed in more than 70 countries around the world.
With over 75 years of experience we have the formulation expertise to tailor your API for optimal solubility, bioavailability, and permeability.
A detailed understanding of the material science of the tablet structure
OptiShell™ capsules utilize a patented shell derived from plant polysaccharides that are ideally suited for the encapsulation of higher melting point fill formulations.
Innovative biotechnology company exploring therapeutics for neuroscience indications
With our expertise and capacity across every phase of development, we offer you the peace of mind that comes from having one company manage your supply chain throughout your product’s entire lifecycle.
How Clinical Supply Management Systems can bring efficiencies to support Project Lifecycle
Global manufacturers are exploring the possibility of producing biosimilars
Bracketing, FMEA , tracking, frequency, along with the introduction of randomized media fills.
Unparalleled graphic capability for softgel capsules provides opportunities to differentiate your product at the unit dose level and deliver a more recognizable, protected and differentiated product
Learn about a global alliance to help streamline the clinical trial material supply process and provide an end-to-end clinical trial material supply solution.
What truly distinguishes our services is our network of globally compliant facilities that provides scalable capacity for all commercial-scale projects in any volume – anywhere in the world.
In today's enviroment solution providers are preferred over CMO's.
CMOs share their opinions on the prospects for their businesses.
An interview with Catalent's Scott Houlton.
Our new, state of the art biologics manufacturing facility—with expanded mammalian cell line engineering and biomanufacturing capabilities utilizing single-use systems—offers increased flexibility and scale to support your growth.
This presentation discusses challenges when considering LBDDS.
Specialized analytical and formulation tools aid in successful, timely Development of LBDDS.
Key considerations for selection, benefits, limitations, and future prospects.
Bend Research and Catalent enter into an agreement to provide integrated solutions.
This webcast will highlight the latest omega-3 drug developments.
This article explores importing clinical trial materials to South America.
Catalent expert Mike Jenkins explains the change Catalent's facility is making.
Explore recent advances in regards to tablet technologies.
Catalent expert interviewed at INTERPHEX 2011 about the blow/fill/seal process.
A comparison between GPEx® and traditional cell line engineering technology.
This article looks into current problems in assuring virological safety of biopharmaceuticals.
Providing a definition for virus safety is nebulous at best.
Catalent expert, Mike Merges, explores practical considerations for bioassays.
Project management is becoming more important as companies increase outsourcing.
Explore overcoming challenges in the tech transfer of biopharma products.
Catalent expert discusses how Catalent is becoming a one-stop shop for global customers.
With our broad range of experience and deep expertise, we have the talent and unique technologies to transform your concepts into excellent results.
Removal of impurities is critical in the purification process for production of final products.
Integrating quality by design into sterile manufacturing facilities is becoming more important.
As a leader in integrated services from molecule to market, we offer stability services for preclinical and clinical studies, drug registration, and commercial products.
Learn about how talent and technology can help grow a company.
This presentation focuses on improving oral delivery for poorly soluble/permeable drugs.
The process of designing, optimizing, validating and implementing your bioassay should be a transparent part of the development cycle that fast-tracks your commercial objectives—not a bottleneck
Integrated services generating fast results Catalent provides the biotechnology industry with an unparalleled range of integrated product development and testing services designed to speed your product development from bench to clinic.
Absence of evidence is not evidence of absence.
Explore the issues with technical transfer in regardss to complex pharmaceutical products
Explore the continuing role of NMR Spectroscopy in characterization of specialty polymers
Investigate the relationship between poorly-soluble drugs and disintegration time of (ODTs)
Evaluate the pharmacokinetic behavior of nanosized fenofibrate administered orally
Disintegration and dissolution characteristics of novel, polysaccharidebased shell softgels
Determination of elemental impurities in support of USP <232> and <233>
Development of digestion methods for determination of elemental impurities
Development and validation of a method for determination of bismuth
From formulation to specialty packaging, this article explores patient adherence.
With over twenty years in inhalation product development, Catalent has the broadest range of development services across all inhaled dose forms.
Explore the power of dual detection methods to identify impurties.
An overview of stability studies during drug product lifecycles.
New data shows drug delivery has a positive impact on patient compliance.
Zydis fast-dissolve formulation for Zelapar (Selegiline anti-Parkinson’s compound) had a positive impact on therapeutic profile vs. Selegiline in traditional tablets.
This presentation details a case study about a phase III global trial.
With global strategic expertise that extends globally, our consultants provide the best solutions for both established and novel pharmaceutical dosage forms across a wide range of therapeutic areas.
Learn more about Catalent's extensive range of advanced, aseptic fill-finish product offerings, tailored to meet the unique needs of each customer provide reliable supply with our network of manufacturing sites.
Find more information on how advanced technologies can create tailored solutions for your toughest drug development challenges and drive faster development timelines.
Softgel technology has been increasingly applied across a wide range of applications including prescription medicines, consumer health, vitamins & mineral supplements and cosmetics.
Softgel is the drug delivery solution of choice that solves complex formulation, solubility, bioavailability, and development challenges, bringing more molecules to market faster.
Our state-of-the-art systems and innovative proprietary technologies will provide you with a strong continuum of services to support your product development needs.
With more than 80 years of experience, our extensive range of technological capabilities can help solve the most complex bioavailability, solubility, and permeability challenges unique to your molecule.
With our broad range of experience and deep expertise, we have the talent and unique technologies to transform your concepts into excellent results.
Our global network of facilities can provide scalable, cost-effective, customized manufacturing options for your complex treatments.
VP of Corporate Strategy and Development discusses emerging drug-delivery technologies.
This presentation deals with the challenges of using suppliers from around the globe
Catalent executive discusses excellence in compliance in Pharmaceutical Formulation & Quality
As the use of “universal” HPLC detectors and charged aerosol detectors become more common
Discussion around the latest trends and issues involving solubility.
Advances in medical discoveries are for nothing if the medicine isn't taken.
Focuses on new innovation drug delivery devices for patient-administered therapies
What sets our GPEx® technology apart from traditional methods is its spot-on reliability by ensuring that stable transductions occur in virtually 100% of target cells.
As the catalyst to improve the total performance of your products, we provide customizable, specialty fill-finish solutions that efficiently drive the most effective patient outcomes.
As the market leader in sterile manufacturing, we offer the latest in innovative fill-finish processes as well as advanced needle safety to improve performance and ensure a patient’s safety.
Learn more about how we design tailored solutions with our superior GPEx® cell line engineering, the SMARTag™ ADC Technology Platform, clinical manufacturing, and integrated services to deliver advanced biologic solutions.
Catelent CEO John Chiminski discusses our offerings
Learn more about how Catalent offers great science, a strong technological infrastructure and extensive expertise to our cosmetic customers with to drive modern trends.
When you use Catalent for pharmaceutical sourcing, you get a global distribution network that can deliver what you need, where you need it and when you need it. Always in the right condition.
Catalent’s chewable is the ideal platform to deliver actives straight into the mouth using our innovative taste masked fill material solutions encapsulated in dissolving shells.
The GOLD program is an intensive, two-year leadership development opportunity designed for university graduates who have a strong desire to accelerate their career growth.
Backed by our team of over 1,000 highly trained scientists, we offer the latest in innovative fill-finish processes, and specialty devices such as auto-injectors.
With over 80 years of experience, we have the deepest expertise, the broadest offerings, and the most innovative technologies to help you get more molecules to market faster, enhance product performance, and provide reliable manufacturing results.
New study shows superior patient compliance with oral fast dissolve delivery
Presentation on ensuring viological safety of biologicals
Exploration of the largest trends in the prefilled syringe and autoinjection devices
Prefilled Syringes Pinpoint Stability, Compatability, and Safety
‘Lean’ is a familiar term in European manufacturing since markets are more competitive
New strategies in formulation development are helping overcome molecule challenges
Softgel Technology as a Lipid-Based Delivery Tool for Bioavailability Enhancement
The aseptic blow-fill-seal (B/F/S) systems have experienced growth.
Case Study: Marchesini Group for Catalent Pharma Solutions: Efficient Syringe Packaging
Catalent experts talk about the increasing demand of prefilled syringes
Presentation detailing inhaled products as well as emerging technologies in this area
Clinical trials are a critical step in the approval process for new drugs.
Use of Peptides in Anti-Aging Cosmetology
Selection of a solid-state form is an important decision in development of small molecule API's
VP of business development discusses blow/fill/seal market and offerings
Fish gelatin support of nanoparticle formation of poorly water-solubles during wet milling
The striking efficiency gains Catalent has achieved with the Lean System for Managing
Modern healthcare challenges and predictions for pharmaceutical market growth
General review of Catalent’s new technology that optimizes API and profitability
Validate method for determination of extractable & leachable silicone oil
Effect of a Kollicoat Top-coat on the physical stability of enteric-coated softgels
Study on the impact of emulsion liposomal liquid and lyophilized liposomal formulations.
Why oral disintegrating tablets are so important to the industry’s oral dose form kit
How manufacturers can partner with contract packagers in new and increasingly complex ways
Explore a cGMP manufacturing model for reducing operating costs and speeding up drugs to market
Pros and cons of options, plus discussion of global problems and lack of foreign security
Laser diffraction particle size analysis – a robust and efficient alternative
Development procedures to reduce antibody effect on Protein Z, with validation results
Study shows import plasticizer level, & potential for migration from coating to shell
Determination of residual solvents in API by headspace GC-MS needs multiple analyses
Implications of FDA release and responsive technologies available to the manufacturer
The more efficient a bioassay method transfer, the faster to regulatory submission
Approach to validate from preclinical development to final commercial implementation
Rapid development model for formulation feasibility & accelerated stability evaluation
Method to separate un-derivatized protein Z (uTPZ) from derivatized TPZ in 3 species
Validate responsive ELISA for the detection of IPZ in monkey, rat, and human serum fluid
Robust options available for micro-dosing inhalation powders with some important caveats
Study investigates design using synthetic molecule recognizing immunoglobulin in serums
Novel approach to validate a method for the determination of water content
New shell and hot-filling that are highly viscous or semi-solid at room temperature
Proven, acceptable NMR spectroscopy test for common EMAs in raw materials and APIs